FFW
SMMT icon

Fusion Family Wealth’s Summit Therapeutics SMMT Stock Holding History

Fusion Family Wealth’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-29,000
Closed -$64K – 271
2018
Q3 		$64K Buy
29,000
+19,000
+190% +$43.8K 0.02% 102
2018
Q2 		$25K Buy
+10,000
New +$128K 0.01% 174

Other funds holding SMMT

LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

Fusion Family Wealth's SMMT Position: Q4 2018 in Review

Fusion Family Wealth sold out of Summit Therapeutics (SMMT) in Q4 2018, closing a stake of 29,000 shares — an estimated $64K sold.

Fusion Family Wealth first reported a position in SMMT in Q2 2018 and held it in 2 quarters. The position peaked at $64K in Q3 2018. 13 funds tracked by Wall St. Rank hold SMMT as of Q4 2018.

  • Fusion Family Wealth reported no remaining Summit Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Fusion Family Wealth sold 29,000 Summit Therapeutics shares in Q4 2018, an estimated $64K.
  • Fusion Family Wealth first reported a position in Summit Therapeutics in Q2 2018 and held it in 2 quarters.
  • Fusion Family Wealth's Summit Therapeutics position peaked at $64K in Q3 2018.
  • 13 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2018.

Based on Fusion Family Wealth's 13F filing for Q4 2018, filed 18 Jan 2019.